Trial Profile
A Phase II Prospective Immune Neoadjuvant Therapy Study od Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms IONESCO
- 21 Sep 2020 Interim results presented at the 45th European Society for Medical Oncology Congress
- 08 Apr 2020 Status changed from recruiting to discontinued.
- 10 May 2019 Planned End Date changed from 1 Jul 2020 to 1 Dec 2023.